Why the study?
Cardio-renal anemia syndrome is a growing problem with high mortality, but differences in the clinical significance and prognostic ability of BNP and NT-proBNP in HF patients with this syndrome remain incompletely elucidated.
Does NT-proBNP have superior prognostic ability compared to BNP in heart failure patients with cardio-renal anemia syndrome?
Does NT-proBNP have superior prognostic ability compared to BNP in heart failure patients with cardio-renal anemia syndrome?
NT-proBNP has superior prognostic ability compared to BNP for predicting cardiac events and mortality in heart failure patients with cardio-renal anemia syndrome.
NT-proBNP may aid risk stratification over BNP in cardio-renal anemia HF; hypothesis-generating and should not yet change practice.
Background: Cardio-renal anemia syndrome (CRAS) is a growing health problem, with a high mortality rate. Brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are well-established diagnostic and prognostic biomarkers of heart failure (HF). The difference in the clinical significance of these biomarkers, however, has not yet been completely elucidated in HF. The aim of the present study was to compare the prognostic ability of BNP and NT-proBNP in HF patients with CRAS.
No takes yet. Share an insight, caveat, or question.
Otaki et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: